[1]
Puranik N, Yadav D, Chauhan PS, et al. Exploring the role of gene therapy for neurological disorders. Curr Gene Ther 2021; 21(1): 11-22. [http://dx.doi.org/ 10.2174/1566523220999200917114101].
[2]
Uddin MS, Hasana S, Hossain MF, et al. Molecular genetics of early- and late-onset Alzheimer’s disease. Curr Gene Ther 2021; 21(1): 43-52. [http://dx.doi.org/10.2174/1566523220666201123112822].
[3]
Singh M, Singh SP, Yadav D, et al. Targeted delivery for neurodegenerative disorders using gene therapy vectors: gene next therapeutic goals. Curr Gene Ther 2021; 21(1): 23-42. [http://dx.doi.org/10.2174/1566523220999200817164907].
[4]
Ashraf GM, Alghamdi BS, Alshehri FS, et al. Standardizing the effective correlated dosage of olanzapine and empagliflozin in female Wistar rats. Curr Gene Ther 2021; 21(1): 53-9. [http://dx.doi.org/10.2174/1566523220999201111195047].
[5]
Uddin MS, Khan ZA, Sumsuzzman DM, et al. Challenges of gene therapy for neurodegenerative disorders. Curr Gene Ther 2021; 21(1): 3-10. [http://dx.doi.org/10.2174/1566523220999201105150442].
Download PDF Flyer